TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06908772: A Multicenter Phase II/III Clinical Study on the Efficacy and Safety of Glumetinib Combined With Osimertinib as First-Line Treatment in Non-Small Cell Lung Cancer Patients With Classical EGFR Mutations Accompanied by MET

Sponsor: Shanghai JMT-Bio Inc. · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 390 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$18,036,480

Rescue Site Savings

+$11,892,804

Unlock Full NCT06908772 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06908772 Rescue Dossier →